Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice

Published:2021-06-01 Issue:6 Volume:37 Page:429-432
ISSN:0889-2229
Container-title:AIDS Research and Human Retroviruses
language:en
Short-container-title:AIDS Research and Human Retroviruses

Author:

Baldin Gianmaria¹²,Ciccullo Arturo²³,Lombardi Francesca⁴,D'Angelillo Anna⁴,Dusina Alex²,Emiliozzi Arianna⁴⁵,Farinacci Damiano⁴,Moschese Davide²,Picarelli Chiara²,Borghetti Alberto²,Di Giambenedetto Simona²⁴

Affiliation:

1. Mater Olbia Hospital, Olbia, Italy.

2. Fondazione Policlinico Agostino Gemelli IRCCS, UOC Malattie Infettive, Roma, Italy.

3. Gemelli Molise Hospital, Campobasso, Italy.

4. Dipartimento di Sicurezza e Bioetica, Sezione di Malattie Infettive, Università Cattolica del Sacro Cuore, Roma, Italy.

5. Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Publisher

Mary Ann Liebert Inc

Subject

Infectious Diseases,Virology,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/aid.2020.0219

Reference11 articles.

1. Impact on Health-Related Quality of Life of a Switch From Enfuvirtide to Raltegravir Among Multidrug-Resistant HIV-1–Infected Patients: A Randomized Open-Label Trial (EASIER-ANRS 138)

2. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

3. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

4. DOLAMA study

5. Dolutegravir plus lamivudine for the treatment of HIV-1 infection

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characteristics and real-world medication persistence of people living with HIV treated with DTG/3TC or BIC/FTC/TAF: a hospital claims database study in Japan;Frontiers in Medicine;2024-09-10

2. Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas;Life;2024-03-28

3. Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV;Journal of Clinical Medicine;2023-12-18

4. Real-Life Experience With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Turkey;Cureus;2023-10-18

5. Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults;PLOS ONE;2023-09-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3